Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The clinical and biochemical effects of treatment with omega-3 fatty acids in patients with homozygous sickle cell disease
source: American Society of Pediatric Hematology/Oncology
year: 2016
authors: Ahmed Daak, West Palm Beach, Kebreab Ghebremeskel, Mustafa Elbashir
summary/abstract:Background: Chronic inflammation, coagulation activation and oxidative stress are increasingly recognized as the major determining factors of acute and chronic clinical manifestations of sickle cell disease (SCD). Several lines of evidence indicate that the anti-inflammatory, anti-aggregatory and anti-oxidant long chance omega-3 fatty acids (n-3) could be a safe and effective modifying therapy for SCD.
Objectives: To demonstrate the clinical and biochemical effects of n-3 fatty acids (DHA and EPA) treatment on SCD.
Design/Method: One hundred forty patients with homozygous SCD (aged 2-24) were randomly assigned and received, daily, 1 (age 2–4 y), 2 (age 5–10 y), 3 (age 11–16), or 4 (age >17 y) omega-3 capsules containing 277.8 mg docosahexaenoic (DHA) and 39.0 mg eicosapentaenoic (EPA) or placebo for 1 year. The rates of clinical vaso-occlusive crisis, hemolytic events, blood transfusion rate, were assessed. The effect of n-3 treatment on markers of inflammation, blood cells adhesion, oxidative stress, coagulation and intravascular hemolysis was investigated.
Results: Omega-3 treatment reduced the median rate of clinical vaso-occlusive events (P> 0.0001), severe anemia (P > 0.05), blood transfusion (0.05), white blood cell count (P> 0.05), plasma lactate dehydrogenase (LDH) , nuclear factor-kappa B (NF-κB) gene expression in buffy coat, expression of monocyte integrin and D-dimer (p>0.05). Omega-3 fatty acid group had significantly higher vitamin E plasma levels. Treatment with n-3 had no significant effect on plasma hs-CRP and plasma plasma tumor necrosis factor-α (TNF-α), (p>0.05).
Conclusion: These findings suggest that treatment with omega-3 fatty acids can be an effective therapeutic option for patents with sickle cell disease.
read moreRelated Content
-
Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari™Emmaus Life Sciences, Inc., a leader in ...
-
The use of cannabis by patients with sickle cell disease increased the frequency of hospitalization due to vaso-occl...Introduction: The objective of this stu...
-
Apheresis Equipment Market is expected to reach USD 3.7 billion by 2024Highlights · The global apheresis eq...
-
FDA Advisory Committee Recommends Approval of Endari™ from Emmaus Life Sciences for the Treatment of Sickle Cell D...Emmaus Life Sciences Inc. announced toda...
-
Study Confirms Safe Use of Opioids for Pain Control in Sickle Cell DiseaseThe most common cause of hospital admiss...
-
Sickle Cell Disease, Hydroxyurea: What You Should Knowhttps://www.onescdvoice.com/wp-content/u...
-
Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Si...BACKGROUND: Sickle cell disease (SCD) is...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.